Clinical Trial Update: ATG-F VS ATG for the Prevention of GVHD [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial comparing ATG-F versus ATG for prevention of graft-versus-host disease in haploidentical hematopoietic stem cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease in the Setting of Haploidentical Hematopoietic Stem Cell Transplantation

Drugs mentioned

• ATG (anti-thymocyte globulin)
• ATG-F (anti-thymocyte globulin fragment F)

Snippet

Sponsor: Fujian Medical University | Conditions: GVHD in the Setting of Haplo-HSCT | Phase 2, Phase 3 | Status: UNKNOWN